Compounders Research Compare

Clearmind Medicine Inc.(CMND)

Biotechnology · Vancouver, BC

$5.78-0.22 (-3.67%)

Delayed quote: Oct 6, 2026, 11:34 AM EDT

About Clearmind Medicine Inc.

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.

Vancouver, BC

4 employees

www.clearmindmedicine.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Adi Zuloff-Shani

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T15:36:10.279Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:36:10.279Z.

Quote observation: 2026-10-06T15:34:21.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,073,311
Total debt · period ending 2026-07-31: 1,798,264
Cash · period ending 2026-07-31: 12,035,210
TTM operating EBITDA · period ending 2026-07-31: -8,810,622

FMP input reference: 003104a745df447911be4c5a9e680832c7b19445192e606e8359fbce1df4db86

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CMND EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CMND Competitors' EV/EBITDA Ratio

Clearmind Medicine Inc.

Current

Market Cap

$1.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aspire Biopharma Holdings, Inc.

Market Cap

$1.02M

EV/EBITDA Ratio

N/A

TTM Avg

1.21x

3Y Avg

1.21x

5Y Avg

1.21x

Cellyan Biotechnology Co., Ltd

Market Cap

$1.11M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Jupiter Neurosciences, Inc.

Market Cap

$1.21M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Propanc Biopharma, Inc.

Market Cap

$1.17M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IM Cannabis Corp.

Market Cap

$1.16M

EV/EBITDA Ratio

N/A

TTM Avg

18.93x

3Y Avg

18.93x

5Y Avg

18.93x

Bone Biologics Corporation

Market Cap

$851060.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GlucoTrack, Inc.

Market Cap

$873967.00

EV/EBITDA Ratio

N/A

TTM Avg

1464.50x

3Y Avg

6462.34x

5Y Avg

6462.34x

Decoy Therapeutics Inc.

Market Cap

$856468.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bluejay Diagnostics, Inc.

Market Cap

$834083.00

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Clearmind Medicine Inc. (CMND)	$1.07M	N/A	N/A	N/A	N/A
Aspire Biopharma Holdings, Inc. (ASBP)vs ›	$1.02M	N/A	1.21x	1.21x	1.21x
Cellyan Biotechnology Co., Ltd (HKPD)vs ›	$1.11M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.21M	N/A	N/A	N/A	N/A
Propanc Biopharma, Inc. (PPCB)vs ›	$1.17M	N/A	N/A	N/A	N/A
IM Cannabis Corp. (IMCC)vs ›	$1.16M	N/A	18.93x	18.93x	18.93x
Bone Biologics Corporation (BBLG)vs ›	$851060.00	N/A	N/A	N/A	N/A
GlucoTrack, Inc. (GCTK)vs ›	$873967.00	N/A	1464.50x	6462.34x	6462.34x
Decoy Therapeutics Inc. (DCOY)vs ›	$856468.00	N/A	N/A	N/A	N/A
Bluejay Diagnostics, Inc. (BJDX)vs ›	$834083.00	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics